Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CTOR
CTOR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CTOR News
Citius Pharmaceuticals Reports $3.9 Million Revenue in Q1 2026
2d ago
PRnewswire
Citius Oncology Reports $3.9 Million in Initial Sales Revenue
2d ago
PRnewswire
Oncolytics Biotech Inc. Reports 33% Response Rate for Pelareorep in Colorectal Cancer
Jan 07 2026
Newsfilter
Oncolytics Biotech's Immunotherapy Shows Significant Improvement in Cancer Treatment Outcomes
Jan 07 2026
PRnewswire
Citius Oncology Under Investigation for Potential Fiduciary Breaches Affecting Shareholders
Jan 05 2026
PRnewswire
Citius Pharmaceuticals Launches LYMPHIR, Stock Surges 22.12%
Dec 24 2025
Benzinga
Citius Oncology Launches LYMPHIR, Completes $36 Million Financing
Dec 23 2025
Newsfilter
Citius Oncology Reports $0.34 Loss Per Share for Fiscal Year Ending September 30
Dec 23 2025
Yahoo Finance
Citius Oncology Launches LYMPHIR™ Cancer Immunotherapy with Market Potential Exceeding $400 Million
Dec 23 2025
PRnewswire
Citius Oncology Launches LYMPHIR, Completes $36 Million Financing
Dec 23 2025
PRnewswire
Citius Oncology Closes $18 Million Financing to Support LYMPHIR Launch
Dec 10 2025
Newsfilter
Citius Oncology Closes $18 Million Financing to Support LYMPHIR Launch
Dec 10 2025
PRnewswire
Citius Oncology Secures $18 Million at $1.09 per Share to Support LYMPHIR Launch
Dec 09 2025
PRnewswire
Citius Oncology Partners with Er-Kim for Exclusive LYMPHIR Distribution in GCC Countries
Dec 04 2025
PRnewswire
Citius Oncology Introduces LYMPHIR, The First New Systemic Treatment for CTCL in More Than Seven Years
Dec 02 2025
NASDAQ.COM
Citius Oncology Launches LYMPHIR, Addressing CTCL Treatment Gap
Dec 01 2025
PRnewswire
Show More News
